ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO827

Obestatin Response to a Meal and Association with Subsequent Appetite Sensations in Maintenance Hemodialysis Patients

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Beberashvili, Ilia, Assaf Harofeh Medical Center, Zerifin, Israel
  • Azar, Ada, Assaf harofeh medical center, Zerifin, Israel
  • Abu hamad, Ramzia, Assaf Harofeh Medical Center, Zerifin, Israel
  • Efrati, Shai, Assaf Harofeh Medical Center, Zerifin, Israel
Background

Obestatin, a physiological opponent of acylated ghrelin, linked to the regulation of appetite reducing food intake in mice but its anorexigenic property in human is controversial. We aimed to investigate a potential role of obestatin in dietary intake regulation by examining response to a meal in maintenance hemodialysis (MHD) patients.

Methods

In this case-control study we have investigated the response of obestatin around a fixed calorie meal (500 kcal) in 21 MHD patients (age 69.2±13.1 years, 10 women, with body mass index 27.2±5.5 kg/m2). Parallel changes in serum obestatin and insulin levels and subjective scores of appetite (visual analogue scales for hunger, satiety, fullness and prospective food consumption) were recorded on fasting and 30, 60 and 120 min after meal.

Results

In a linear mixed effects model controlling for baseline demographics and clinical parameters including serum insulin concentrations, postprandial levels of obestatin did not change significantly from baseline in response to the meal. The response was the same in MHD patients treated with high or low flux dialyzers. However, postprandial obestatin levels were associated with the rate of change in sensation of fullness (linear estimate: 11.60 (95% confidence interval 0.17 to 23.04, P<0.05). The remained sensations of appetite did not correlate with postprandial obestatin levels in time.

Conclusion

Obestatin levels do not change acutely with food administration in MHD patients, but associate with the changes in sensation of fullness. This supports the possible role of obestatin in the long-term regulation of appetite in MHD population.